Table 4.
Treatment-related toxicities between the TPF and TP groups.
| Variables | TPF (n = 128) | TP (n = 85) | P | |||||
|---|---|---|---|---|---|---|---|---|
| Grade 0 (%) | Grade 1-2 (%) | Grade 3-4 (%) | Grade 0 (%) | Grade 1-2 (%) | Grade 3-4 (%) | Grade 1-2 | Grade 3-4 | |
| Leukopenia | 20 (15.63) | 56 (43.75) | 52 (40.62) | 24 (28.24) | 30 (35.29) | 31 (36.47) | 0.380 | 0.038 |
| Neutropenia | 28 (21.88) | 65 (50.78) | 35 (27.34) | 33 (38.82) | 40 (47.06) | 12 (14.12) | 0.465 | 0.021 |
| Anemia | 46 (35.94) | 78 (60.94) | 4 (3.12) | 36 (42.35) | 47 (55.29) | 2 (2.36) | 0.583 | 0.154 |
| Thrombocytopenia | 44 (34.38) | 82 (64.06) | 2 (1.56) | 28 (32.94) | 56 (65.88) | 1 (1.18) | 0.435 | 0.083 |
| Abnormal liver function | 46 (35.94) | 81 (63.28) | 1 (0.78) | 26 (30.59) | 58 (68.23) | 1 (1.18) | 0.363 | 0.215 |
| Abnormal renal function | 48 (37.50) | 79 (61.72) | 1 (0.78) | 32 (37.65) | 53 (62.35) | 0 (0.00) | 0.672 | 0.276 |
| Vomiting | 23 (17.97) | 90 (70.31) | 15 (11.72) | 12 (14.12) | 59 (69.41) | 14 (16.47) | 0.574 | 0.426 |
| Oral mucositis | 26 (20.31) | 65 (50.78) | 37 (28.91) | 23 (27.06) | 50 (58.82) | 12 (14.12) | 0.375 | 0.048 |
| Diarrhea | 18 (14.06) | 75 (58.60) | 35 (27.34) | 17 (20.00) | 59 (69.41) | 9 (10.59) | 0.584 | 0.036 |
| Osteonecrosis | 126 (98.44) | 2 (1.56) | 0 (0.00) | 84 (98.82) | 1 (1.18) | 0 (0.00) | 0.746 | 0.548 |
| Ear (deafness/otitis) | 89 (69.53) | 21 (16.41) | 18 (14.06) | 65 (76.47) | 11 (12.94) | 9 (10.59) | 0.147 | 0.046 |
| Radiation-induced malignancy | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | – | – |
TPF, docetaxel, cisplatin, and 5-fluorouracil; TP, docetaxel and cisplatin.